Over the past months, Saphetor has been scaling its global distribution network at full gallop. The global precision medicine company has signed a new partnership with Roche Turkey giving the pharma giant access to its network to facilitate scientific collaborations on new treatments for Spinal Muscular Atrophy.
Saphetor is the leader in diagnostic and bioinformatics solutions for clinical Next Generation Sequencing (NGS). The company developed VarSome Clinical, a clinically-certified platform for allowing fast and accurate interpretation of NGS data, which helps clinicians reach faster and more accurate diagnoses and treatment decisions for genetic conditions. The VarSome.com search engine and professional community is freely accessible, featuring a widely-recognized community-driven knowledge base that enables flexible queries across more than 50 genetic and genomic data resources.
The startup has been actively expanding its global distribution network with new partners across the world to promote VarSome. To date, labs in more than 25 countries in Europe, Australia, Asia, Africa and the Americas can access the platform.
Through a partnership with Roche Turkey, Saphetor, through Varsome.com will facilitate connecting labs that wish to partner with Roche on drug discovery initiatives of Spinal Muscular Atrophy (SMA). The goal will be to create and foster relationships as well as to accelerate scientific collaboration on SMA. Exploring new and more efficient ways for scientific collaboration has long been an obstacle in the pharmaceutical industry. Saphetor is hence helping to avoid the loss of critical time through identifying the most relevant patients and facilitating the communication between involved parties such as labs, pharma and patients.
Andreas Massouras, CEO of Saphetor commented: “We are very excited to partner with Roche and contribute to their important effort in developing treatments for this debilitating and often lethal disease. VarSome.com is proving an extremely valuable resource for willing clinical and research labs as well as pharmaceutical companies to collaborate on a worldwide level.”
Anne Nijs, Transformation Leader, Rare Conditions for Pharma International at Roche said: “We look forward to leveraging Saphetor’s innovative approach to bring together the global genomics community in order to connect with the right participants in the healthcare ecosystem of rare disorders.”
(Press release)
Please login or sign up to comment.
Commenting guidelines